ASCO: Halozyme's pancreatic cancer therapy is safe with chemo combo
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics may have an important pancreatic cancer treatment-boosting agent in its portfolio of therapeutic enzymes, but the San Diego-based company will not know for a year or more whether tumor responses seen in Phase Ib translate to a clinical benefit in Phase II.